Holen Sie sich die Stockscreener-App
9.24
1.87%
0.17
Schlusskurs vom Vortag:
$9.07
Offen:
$9.11
24-Stunden-Volumen:
70,041
Relative Volume:
0.80
Marktkapitalisierung:
$46.11M
Einnahmen:
$34.77M
Nettoeinkommen (Verlust:
$-74.04M
KGV:
-1.1527
EPS:
-8.0157
Netto-Cashflow:
$-79.76M
1W Leistung:
+11.59%
1M Leistung:
+25.71%
6M Leistung:
+41.39%
1J Leistung:
-80.55%
1-Tages-Spanne:
$8.745
$9.28
1-Wochen-Bereich:
$7.8275
$9.50
52-Wochen-Spanne:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
9.24 | 45.27M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | William Blair | Outperform |
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Why Mersana Therapeutics Inc. stock remains a top recommendation2025 Buyback Activity & Entry Point Confirmation Alerts - newser.com
Why Mersana Therapeutics Inc. is moving todayJuly 2025 Earnings & Verified High Yield Trade Plans - newser.com
Mersana initiated at outperform at William Blair on antibody-drug conjugate potential - MSN
Does Mersana Therapeutics Inc. fit your quant trading modelFed Meeting & Safe Entry Zone Tips - newser.com
Relative strength of Mersana Therapeutics Inc. in sector analysis2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 26% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Mersana Therapeutics (NASDAQ:MRSN) Stock Price Down 3.9% – Should You Sell? - Defense World
What MACD and RSI say about Mersana Therapeutics Inc.2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
Why Mersana Therapeutics Inc. (0M4) stock attracts HNW investors2025 Pullback Review & Expert Curated Trade Ideas - newser.com
What valuation multiples suggest for Mersana Therapeutics Inc. stockJobs Report & Verified Momentum Stock Ideas - newser.com
What MACD signals say about Mersana Therapeutics Inc.2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Is Mersana Therapeutics Inc. stock bottoming outMarket Growth Report & Stepwise Trade Signal Implementation - newser.com
Is this a good reentry point in Mersana Therapeutics Inc.Short Setup & Daily Risk Controlled Trade Plans - newser.com
What drives Mersana Therapeutics Inc stock pricePrice Volatility Patterns & Build Winning Strategies With Zero Cost - earlytimes.in
How resilient is Mersana Therapeutics Inc. stock in market downturns2025 Major Catalysts & Community Verified Swing Trade Signals - newser.com
Pattern recognition hints at Mersana Therapeutics Inc. upsideJuly 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Is Mersana Therapeutics Inc a good long term investment - earlytimes.in
How Mersana Therapeutics Inc. stock compares to industry benchmarks2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com
Will Mersana Therapeutics Inc. stock beat EPS estimatesMarket Growth Report & Community Verified Trade Alerts - newser.com
Will a bounce in Mersana Therapeutics Inc. offer an exitEarnings Beat & AI Enhanced Execution Alerts - newser.com
How to use Fibonacci retracement on Mersana Therapeutics Inc.Breakout Watch & Comprehensive Market Scan Reports - newser.com
What technical models suggest about Mersana Therapeutics Inc.’s comebackJuly 2025 Catalysts & Weekly Chart Analysis and Guides - newser.com
Published on: 2025-10-03 01:27:08 - newser.com
Published on: 2025-10-02 20:29:11 - newser.com
Is Mersana Therapeutics Inc. (0M4) stock supported by free cash flowWeekly Gains Summary & Detailed Earnings Play Strategies - newser.com
Applying Wyckoff theory to Mersana Therapeutics Inc. stock2025 Market Sentiment & Free Community Supported Trade Ideas - newser.com
Mersana Therapeutics Inc Stock Analysis and ForecastVolume Profile Analysis & Fast Profit Investment Ideas - earlytimes.in
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mersana Therapeutics Inc-Aktie (MRSN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Huber Martin H. Jr. | President, CEO |
Sep 12 '25 |
Sale |
7.31 |
2,012 |
14,708 |
9,572 |
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
8,685 |
0 |
61,073 |
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):